HilleVax, Inc. (HLVX)
Fuera de horario:
HilleVax, Inc.
321 Harrison Avenue
5th floor
Boston, MA 02118
United States
617 213 5054
https://www.hillevax.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 90
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, CEO & Chairman of the Board | 1.04M | N/D | 1962 |
| Dr. Aditya Kohli Ph.D. | Co-Founder, Chief Business Officer & Director | 765.87k | N/D | 1988 |
| Ms. Astrid Borkowski M.D., Ph.D. | Chief Medical Officer | 854.56k | N/D | 1970 |
| Mr. Shane A. Maltbie | CFO & Treasurer | N/D | N/D | 1982 |
| Mr. Sean McLoughlin | Chief Operating Officer | N/D | N/D | 1972 |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
| Mr. Paul S. Bavier J.D. | General Counsel, Secretary & Chief Administrative Officer | N/D | N/D | 1972 |
| Mr. Ozzie Berger | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de HilleVax, Inc. a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 3; Junta: 10; Derechos del accionista: 8; Compensación: 9.
